While bempegaldesleukin has yielded disappointing phase 3 clinical trial results, other IL-2 variants in clinical development that rely on different mechanisms of action hold promise for significantly expanding the therapeutic index of IL-2 with more effective induction and activation of anti-tumor cytotoxic T cells, including THOR-707 and TransCon IL-2 β/γ. Here, IL2 is linked to neoplasm.